AU2012347758B2 - Composition and method for neuropeptide S receptor (NPSR) antagonists - Google Patents

Composition and method for neuropeptide S receptor (NPSR) antagonists Download PDF

Info

Publication number
AU2012347758B2
AU2012347758B2 AU2012347758A AU2012347758A AU2012347758B2 AU 2012347758 B2 AU2012347758 B2 AU 2012347758B2 AU 2012347758 A AU2012347758 A AU 2012347758A AU 2012347758 A AU2012347758 A AU 2012347758A AU 2012347758 B2 AU2012347758 B2 AU 2012347758B2
Authority
AU
Australia
Prior art keywords
compound
phenyl
tetrahydrofuro
pyridin
isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012347758A
Other languages
English (en)
Other versions
AU2012347758A1 (en
Inventor
Brian GILMOUR
Carla HASSLER
Scott RUNYON
Yanan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International
Original Assignee
RTI International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International filed Critical RTI International
Publication of AU2012347758A1 publication Critical patent/AU2012347758A1/en
Application granted granted Critical
Publication of AU2012347758B2 publication Critical patent/AU2012347758B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU2012347758A 2011-12-08 2012-12-06 Composition and method for neuropeptide S receptor (NPSR) antagonists Active AU2012347758B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568540P 2011-12-08 2011-12-08
US61/568,540 2011-12-08
PCT/US2012/068257 WO2013086200A1 (en) 2011-12-08 2012-12-06 Composition and method for neuropeptide s receptor (npsr) antagonists

Publications (2)

Publication Number Publication Date
AU2012347758A1 AU2012347758A1 (en) 2014-06-05
AU2012347758B2 true AU2012347758B2 (en) 2017-01-19

Family

ID=48574884

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012347758A Active AU2012347758B2 (en) 2011-12-08 2012-12-06 Composition and method for neuropeptide S receptor (NPSR) antagonists

Country Status (7)

Country Link
US (1) US9150582B2 (cg-RX-API-DMAC7.html)
EP (1) EP2788359B1 (cg-RX-API-DMAC7.html)
JP (1) JP6381445B2 (cg-RX-API-DMAC7.html)
AU (1) AU2012347758B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858571C (cg-RX-API-DMAC7.html)
ES (1) ES2624853T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013086200A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017246706B2 (en) * 2016-04-04 2020-09-17 Research Triangle Institute Neuropeptide s receptor (NPSR) agonists
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055491A2 (en) * 2001-01-11 2002-07-18 Bristol Myers Squibb Company P 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4917489B1 (cg-RX-API-DMAC7.html) * 1970-01-22 1974-05-01
EP0140833B1 (de) * 1983-09-15 1988-03-02 Ciba-Geigy Ag 5-und 6-Azaphthalide, ihre Isomerengemische, Verfahren zu ihrer Herstellung und ihre Verwendung in druck- und wärmeempfindlichen Aufzeichnungsmaterialien
EP0558521A1 (en) * 1990-11-22 1993-09-08 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives and related spiro compounds with herbicidal action
EP1329508B1 (en) 2000-10-13 2010-09-08 Takeda Pharmaceutical Company Limited Novel g protein-coupled receptor protein and dna thereof
US9012407B2 (en) * 2004-04-23 2015-04-21 The Regents Of The University Of California Therapies which act on neuropeptide S receptors
EP2365748A4 (en) * 2008-11-13 2012-05-02 Merck Sharp & Dohme IMIDAZOISOINDOL neuropeptide S RECEPTOR ANTAGONISTS
EP2365749A4 (en) * 2008-11-13 2012-05-30 Merck Sharp & Dohme Quinolone NEURO PEPTIDE-S-Receptor Antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055491A2 (en) * 2001-01-11 2002-07-18 Bristol Myers Squibb Company P 1,2-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLORPROTEASES AND TNF-$g(a)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPSZTAJN J. ET. AL. TETRAHEDRON LETTERS, vol . 21, no. 49, 1 December 1980, pages 4739-4742, *
TEWARI J. D. : "Dyes derived from Cinchomeronic Acid" JOURNAL OF THE CHEMICAL SOCIETY, vol. 1929, 1 October 1929 pages 1642-1644 *
XUE, C.-B. et al. Synthesis and Structure-Activity Relationship of a Novel Sulfone Series of TNF-a Converting Enzyme Inhibitors. Bioorganic & Medicinal Chemistry Letters. 2004, Vol.14, pages 4453-4459. *

Also Published As

Publication number Publication date
EP2788359A4 (en) 2015-06-10
CA2858571C (en) 2021-03-16
AU2012347758A1 (en) 2014-06-05
US9150582B2 (en) 2015-10-06
JP2015500293A (ja) 2015-01-05
CA2858571A1 (en) 2013-06-13
WO2013086200A1 (en) 2013-06-13
ES2624853T3 (es) 2017-07-17
EP2788359A1 (en) 2014-10-15
US20150057268A1 (en) 2015-02-26
EP2788359B1 (en) 2017-03-01
JP6381445B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
KR102038161B1 (ko) Nmda 수용체 조절물질 및 그의 용도
US7935721B2 (en) Spiro-oxindole compounds and their uses as therapeutic agents
KR101769999B1 (ko) Nmda 수용체 조절제 및 그의 용도
AU2007319580B2 (en) Use of spiro-oxindole compounds as therapeutic agents
US6410548B2 (en) Spiropiperidine derivatives as melanocortin receptor agonists
EP2951185B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
RU2572818C2 (ru) Производное тетрагидрокарболина
JP2015520140A (ja) APP、BACE1、およびBACE2の阻害剤としての複素環式置換ヘキサヒドロピラノ[3,4−d][1,3]チアジン−2−アミン化合物
KR20060058104A (ko) 벤즈아미드 치환체를 갖는 사이클릭 아민 bace-1억제제
BRPI0609887A2 (pt) composto, composição farmacêutica, métodos para tratar uma infecção bacteriana, e para inibir dna girase bacteriana em um animal de sangue quente, e, processo para fabricar um composto
EP1301516A1 (en) Modulators of protein tyrosine phosphatases (ptpases)
CA2858571C (en) Composition and method for neuropeptide s receptor (npsr) antagonists
CA3207747A1 (en) Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
IL228985A (en) Diazonamide analogs
CN113527172B (zh) M2乙酰胆碱受体拮抗剂及其用途
RU2792034C2 (ru) Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение
CA3018344C (en) Neuropeptide s receptor (npsr) agonists
CN115073449A (zh) 稠环杂环化合物及应用、含有其的药物组合物及应用
HK1168104B (en) Spiro-oxindole compounds and their uses as therapeutic agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)